Zolgensma denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for zolgensma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Zolgensma as Non-Formulary

Zolgensma (onasemnogene abeparvovec) is a gene therapy administered as a single infusion and is not distributed through a retail or specialty pharmacy like a conventional drug — it is typically handled as a medical benefit rather than a pharmacy benefit. Because of this, some UnitedHealthcare plans either do not list Zolgensma on the pharmacy formulary at all or require a separate prior authorization pathway under the medical benefit. A non-formulary denial often reflects a benefit-routing issue as much as an outright coverage refusal.

Understanding which benefit tier applies to Zolgensma under your specific plan is the critical first step. Your prescriber's office and the treating infusion center should help clarify whether the claim should be submitted under the pharmacy benefit or the medical/surgical benefit. If the denial is truly a formulary exclusion, an exceptions process is available.

## Your Appeal Rights

• Formulary exception request: Most plans offer a formulary exception process separate from the standard appeal. Your physician must submit documentation showing that all formulary alternatives are medically inappropriate or contraindicated for this patient. This is distinct from — and often faster than — a formal appeal.
• Internal appeal (ERISA §503 / ACA §2719): If the exception is denied, file a formal internal appeal. Employer-plan members are entitled to a full-and-fair review. After an adverse internal decision, you have the right to independent external review, generally within a four-month window.
• Expedited review: If the patient's clinical condition is deteriorating and delay poses a serious risk, request expedited external review, which must be completed within 72 hours.

## Documentation to Gather

1. Benefit routing clarification — confirm in writing from UHC whether Zolgensma is processed as a pharmacy or medical benefit under this plan, and request the applicable coverage policy. 2. Diagnosis and genetic confirmation — genetic test results confirming SMA with SMN1 status and SMN2 copy number. 3. Clinical chart records — dated motor function assessments, pulmonary notes, and disease staging from the neurologist. 4. Formulary alternative assessment — your prescriber's written explanation of why each formulary SMA therapy (if any) is medically inappropriate, contraindicated, or insufficient for this patient's situation. 5. Prescriber medical-necessity letter — addressing why Zolgensma specifically is required, citing the FDA prescribing label and applicable professional society guidance.

## Criteria-Mapping Structure

Request UnitedHealthcare's current coverage policy for Zolgensma and the FDA-approved prescribing information. Map each criterion:

| Criterion | Documentation | |---|---| | Confirmed SMA diagnosis with genetic data | Lab report, [date] | | Disease type and severity | Neurologist note, [date] | | Medical inappropriateness of formulary alternatives | Prescriber letter, [date] | | Age / weight / disease stage per label | Chart entry, [date] |

If the denial stems from a benefit-routing error, the fastest resolution is often a corrected claim submission rather than a full appeal — your specialty pharmacy coordinator or the infusion site's billing team can guide this. When a genuine formulary exclusion applies, the exception and appeal path described above is your best route.